Erasca, Inc.
10835 Road to the Cure, Suite 140
San Diego, CA 92121
July 13, 2021
VIA EDGAR
Ms. Tonya K. Aldave
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Erasca, Inc. |
Registration Statement on Form S-1
File No. 333-257436
Dear Ms. Aldave:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Erasca, Inc. (the “Company”), respectfully requests that the effective date of the Registration Statement on Form S-1 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on July 15, 2021, or as soon as practicable thereafter.
Please contact Matthew T. Bush of Latham & Watkins LLP, counsel to the Company, at (858) 523-3962, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.
| Very truly yours, | ||
| ERASCA, INC. | ||
| By: | /s/ Jonathan E. Lim | |
| Jonathan E. Lim, M.D. | ||
| Chairman and Chief Executive Officer | ||
cc:
Sonia Bednarowski, Securities and Exchange Commission
Angella Connell, Securities and Exchange Commission
Julie Sherman, Securities and Exchange Commission
David M. Chacko, M.D., Erasca, Inc.
Ebun S. Garner, Erasca, Inc.
Cheston J. Larson, Latham & Watkins LLP
Matthew T. Bush, Latham & Watkins LLP
Alaina P. Ellis, Latham & Watkins LLP